Abstract
Despite recent progress obtained from perioperative chemotherapy and particularly, that demonstrated by the clinical trials on adjuvant chemotherapy, recurrences remain frequent after surgery for non-small cell lung cancer. Research on adjuvant treatments is ongoing, focused on targeted therapies or personalised therapeutic strategies. Other questions remain unanswered and are still investigated in clinical trials by the French Cancer Institute, such as thoracic radiotherapy for N2 disease, surveillance and treatment of recurrences. Although post-surgical surveillance, with or without chemotherapy, may theoretically increase survival by an earlier detection of recurrences, there are no evidence-based data. With the wide use of adjuvant chemotherapy, the profile of recurrences is likely to change and the best chemotherapy for metastatic recurrences remains to be defined.
Résumé
Malgré les progrès thérapeutiques récents, obtenus avec la chimiothérapie périopératoire, en particulier démontrés par les essais de chimiothérapie adjuvante, les rechutes après chirurgie d’un carcinome bronchique non à petites cellules restent fréquentes. Les efforts de recherche se pousuivent dans le cadre des traitements adjuvants, avec des essais intégrant les thérapeutiques ciblées et évaluant des stratégies thérapeutiques personnalisées. D’autres questions n’ont actuellement aucune réponse et font l’objet d’essais cliniques conduits sous l’égide de l’IFCT, tels que la radiothérapie postopératoire des N2, la surveillance et le traitement des rechutes. La surveillance après chirurgie ± chimiothérapie, bien que théoriquement susceptible d’améliorer la survie par une détection plus précoce des rechutes, ne repose actuellement sur aucune donnée scientifique solide. Avec l’avènement des chimiothérapies périopératoires, le profil des rechutes est susceptible de se modifier, et la meilleure chimiothérapie à délivrer lors de rechutes métastatiques reste à définir.
Similar content being viewed by others
Références
Dautzenberg B, Arriagada R, Chammard AB, et al. (1999) A controlled study of postoperative radiotherapy for patients with completely resected non-small cell lung carcinoma. Cancer 86: 265–273
Douillard JY, Rosell R, De Lena M, et al. (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7(9): 719–727
Gilbert S, Reid KR, Lam MY, Petsikas D (2000) Who should follow-up lung cancer patients after operation? Ann Thorac Surg 69(6): 1696–1700
Ichinose Y, Kato H, Koike T, et al., Japan Clinical Oncology Group (2001) Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 34: 29–36
International Adjuvant Lung cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350: 351–360
Keller SM, Adak S, Wagner H, et al., for the Eastern Cooperative Oncology Group (2000) A randomised trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small cell lung cancer. N Engl J Med 343: 1217–1222
Lally BE, Zelterman D, Colasanto JM, et al. (2006) Postoperative radiotherapy for stage II or III non-small cell lung cancer using the surveillance epidemiology and end results database. J Clin Oncol 24: 2998–3006
Martini N, Melamed M (1975) Multiple primary lung cancers. J Thorac Cardiovasc Surg 70: 606–612
Non Small Cell Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899–909
Olaussen KA, Dunant A, Fouret P, et al. (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983–991
Pfister DG, Johnson DH, Azzoli CG, et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22(2): 330–353
PORT Meta-analysis Trialists Group (1998) Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352: 257–263
Rubins J, Unger M, Colice GL (2007) Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 132(Suppl 3): 355S–367S
Scagliotti GV, Fossati R, Torri V, et al., for the ALPI/EORTC Cooperative Group Investigators (2003) Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Nat Cancer Inst 95: 1453–1461
Stephens RJ, Girling DJ, Bleehen NM, et al., for the Medical Research Council Lung Cancer Working Party (1996) The role of postoperative radiotherapy in non-small cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1–T2, N1–N2, M0 disease. Br J Cancer 74: 632–639
Strauss G, Herndon J, Maddaus M, et al. (2006) Adjuvant chemotherapy in Stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 24: 7007 (annual meeting proceedings)
Tada H, Tsuchiya R, Ichinose Y, et al. (2004) A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 43: 167–173
Virgo KS, McKirgan LW, Caputo MC, et al. (1995) Post-treatment management options for patients with lung cancer. Ann Surg 222(6): 700–710
Waller D, Peake MD, Stephens RJ, et al. (2004) Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardio-Thorac Surg 26: 173–182
Walsh GL, O’Connor M, Willis KM, et al. (1995) Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 60(6): 1563–1570
Westeel V, Choma D, Clément F, et al. (2000) Relevance of an intensive post-operative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg 70: 1185–1190
Winton TL, Livingston R, Johnson D, et al. (2005) Vinorelbine plus cisplatin versus observation in resected non-small cell lung cancer. N Engl J Med 352: 2589–2597
Younes RN, Gross JL, Deheinzelin D (1999) Follow-up in lung cancer: how often and for what purpose? Chest 115(6): 1494–1499
Author information
Authors and Affiliations
Corresponding authors
About this article
Cite this article
Westeel, V., Moro-Sibilot, D. Prise en charge oncologique du patient opéré: chimiothérapie adjuvante, surveillance, traitement des rechutes. Oncologie 10, 525–528 (2008). https://doi.org/10.1007/s10269-008-0953-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-008-0953-9